🚀 VC round data is live in beta, check it out!
Walvax Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Walvax Biotechnology and similar public comparables like Brightgene Bio-medical, Betta Pharmaceuticals, China Res Double-Crane, Beam Therapeutics and more.
Walvax Biotechnology Overview
About Walvax Biotechnology
Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products.
Founded
2001
HQ
Employees
2.4K
Website
Sectors
Financials (LTM)
EV
$3B
Walvax Biotechnology Financials
Walvax Biotechnology reported last 12-month revenue of $375M and EBITDA of $98M.
In the same LTM period, Walvax Biotechnology generated $98M in EBITDA and $28M in net income.
Revenue (LTM)
Walvax Biotechnology P&L
In the most recent fiscal year, Walvax Biotechnology reported revenue of $406M and EBITDA of $83M.
Walvax Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $375M | XXX | $406M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $323M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $98M | XXX | $83M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 10% | XXX | XXX | XXX |
| Net Profit | $28M | XXX | $20M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Walvax Biotechnology Stock Performance
Walvax Biotechnology has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Walvax Biotechnology's stock price is $1.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | -0.9% | XXX | XXX | XXX | $0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWalvax Biotechnology Valuation Multiples
Walvax Biotechnology trades at 6.8x EV/Revenue multiple, and 26.0x EV/EBITDA.
EV / Revenue (LTM)
Walvax Biotechnology Financial Valuation Multiples
As of March 18, 2026, Walvax Biotechnology has market cap of $3B and EV of $3B.
Equity research analysts estimate Walvax Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Walvax Biotechnology has a P/E ratio of 96.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 26.0x | XXX | 30.6x | XXX | XXX | XXX |
| EV/EBIT | 64.8x | XXX | 60.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.9x | XXX | XXX | XXX |
| P/E | 96.7x | XXX | 134.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 36.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Walvax Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Walvax Biotechnology Margins & Growth Rates
Walvax Biotechnology's revenue in the last 12 month grew by 16%.
Walvax Biotechnology's revenue per employee in the last FY averaged $0.2M.
Walvax Biotechnology's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Walvax Biotechnology's rule of X is 67% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Walvax Biotechnology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | (11%) | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 21% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Walvax Biotechnology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Brightgene Bio-medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Betta Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| China Res Double-Crane | XXX | XXX | XXX | XXX | XXX | XXX |
| Beam Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kalbe Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Walvax Biotechnology M&A Activity
Walvax Biotechnology acquired XXX companies to date.
Last acquisition by Walvax Biotechnology was on XXXXXXXX, XXXXX. Walvax Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Walvax Biotechnology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWalvax Biotechnology Investment Activity
Walvax Biotechnology invested in XXX companies to date.
Walvax Biotechnology made its latest investment on XXXXXXXX, XXXXX. Walvax Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Walvax Biotechnology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Walvax Biotechnology
| When was Walvax Biotechnology founded? | Walvax Biotechnology was founded in 2001. |
| Where is Walvax Biotechnology headquartered? | Walvax Biotechnology is headquartered in China. |
| How many employees does Walvax Biotechnology have? | As of today, Walvax Biotechnology has over 2K employees. |
| Is Walvax Biotechnology publicly listed? | Yes, Walvax Biotechnology is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Walvax Biotechnology? | Walvax Biotechnology trades under 300142 ticker. |
| When did Walvax Biotechnology go public? | Walvax Biotechnology went public in 2011. |
| Who are competitors of Walvax Biotechnology? | Walvax Biotechnology main competitors are Brightgene Bio-medical, Betta Pharmaceuticals, China Res Double-Crane, Beam Therapeutics. |
| What is the current market cap of Walvax Biotechnology? | Walvax Biotechnology's current market cap is $3B. |
| What is the current revenue of Walvax Biotechnology? | Walvax Biotechnology's last 12 months revenue is $375M. |
| What is the current revenue growth of Walvax Biotechnology? | Walvax Biotechnology revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Walvax Biotechnology? | Current revenue multiple of Walvax Biotechnology is 6.8x. |
| Is Walvax Biotechnology profitable? | Yes, Walvax Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Walvax Biotechnology? | Walvax Biotechnology's last 12 months EBITDA is $98M. |
| What is Walvax Biotechnology's EBITDA margin? | Walvax Biotechnology's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Walvax Biotechnology? | Current EBITDA multiple of Walvax Biotechnology is 26.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.